Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a substituted benzimidazole proton pump inhibitor (PPI) that suppresses gastric acid secretion by inhibiting the H+/K+-ATPase enzyme system at the secretory surface of the gastric parietal cell.
## Primary Indications
* Erosive esophagitis associated with GERD.
* Maintenance of healing of erosive esophagitis.
* Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome).
* Short-term treatment of GERD symptoms.
## Adult Dosing
* **Erosive Esophagitis:** 40 mg PO/IV once daily for up to 8 weeks.
* **Maintenance of Healing:** 40 mg PO once daily.
* **Hypersecretory Conditions:** Starting dose 40 mg PO twice daily. Doses up to 240 mg/day have been used; adjust based on patient needs.
* **GERD (Short-term):** 40 mg PO once daily for 4 weeks.
## Pediatric Dosing
* **Age ≥5 years (Erosive Esophagitis):**
* 15 kg to <40 kg: 20 mg once daily.
* ≥40 kg: 40 mg once daily.
* **Safety/Efficacy:** Usage is established for short-term treatment (up to 8 weeks) in pediatric patients 5 years and older.
## Dose Adjustments
* **Renal Impairment:** No dose adjustment necessary.
* **Hepatic Impairment:** Reduce dosage or frequency in severe liver disease; monitor closely.
## Contraindications
* Known hypersensitivity to pantoprazole or any component of the formulation.
* Concomitant use with rilpivirine-containing products.
## Adverse Effects
* **Common:** Headache, diarrhea, nausea, abdominal pain, flatulence.
* **Serious:** *Clostridioides difficile*-associated diarrhea, hypomagnesemia, vitamin B12 deficiency (with long-term use), acute interstitial nephritis, and increased risk of bone fractures (osteoporosis-related).
## Key Drug Interactions
* **pH-Dependent Absorption:** May decrease absorption of drugs like atazanavir, nelfinavir, iron salts, and certain azole antifungals (e.g., ketoconazole).
* **Clopidogrel:** Potential for reduced antiplatelet effect, though clinical significance remains debated; monitor for cardiovascular events.
* **Methotrexate:** PPIs may increase serum levels of methotrexate, particularly in high-dose therapy.
## Monitoring
* Baseline and periodic serum magnesium levels if on long-term therapy or concomitant diuretics.
* Monitor for signs of *C. difficile* infection (e.g., persistent watery diarrhea).
* Assess for vitamin B12 deficiency in long-term users.
## Clinical Pearls
* **Administration:** Tablets can be taken without regard to meals. If using oral suspension, administer 30 minutes before a meal. IV formulation should be administered as a 15-minute infusion.
* **Duration:** PPIs should be used for the shortest duration necessary. Tapering may be required to avoid rebound acid hypersecretion upon discontinuation.
* **Formulation:** Tablets must be swallowed whole; do not crush or chew.
***
*Disclaimer: This information is for educational purposes and does not replace professional clinical judgment. Always verify dosages, contraindications, and drug interactions against current institutional protocols and the most up-to-date prescribing information (e.g., Package Insert or resources like Lexicomp/Clinical Pharmacology).*
